Eliglustat-d15 (tartrate) – 5 mg

Brand:
Cayman
CAS:
1884556-84-6
Storage:
-20
UN-No:
Non-Hazardous - /

Eliglustat-d15 is intended for use as an internal standard for the quantification of eliglustat (Item No. 21487) by GC- or LC-MS. Eliglustat is an inhibitor of glucosylceramide synthase (IC50 = 40 nM for inhibition of glucosylceramide production in K562 cells).{41053} It is selective for glucosylceramide synthase over α-glucosidase I and II, α-1,6-glucosidase, lysosomal glucocerebrosidase, non-lysosomal glucosylceramidase, sucrase, and maltase (IC50s = >10 µM for all). It decreases cell surface levels of the gangliosides GM1 and GM3 in K562 and B16/F10 cells with IC50 values of 24 and 29 nM, respectively. Eliglustat (150 mg/kg per day) decreases glucosylceramide levels in the liver and lungs of D409V/null mice, a model of Gaucher disease. Formulations containing eliglustat have been used in the treatment of type 1 Gaucher disease.  

 

Available on backorder

SKU: 30167 - 5 mg Category:

Description

An internal standard for the quantification of eliglustat by GC- or LC-MS


Formal name: N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-octanamide-2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-d15, (2R,3R)-2,3-dihydroxybutanedioate

Synonyms: 

Molecular weight: 569.7

CAS: 1884556-84-6

Purity: ≥99% deuterated forms (d1-d15)

Formulation: A solid